A recent study led by Harvard Medical School and a Brazil-based contract research organization called INTRIALS reveals that a proprietary anti-CD3 human monoclonal antibody targeting COVID-19 called Foralumab shows evidence that the nasally administered investigational product reduced pulmonary and systemic inflammation and is well tolerated. In development by a biotech venture called Tiziana Life Sciences (NASDAQ: TLSA/LSE: TILS) focused on innovative therapeutics for oncology, inflammation and infectious diseases, the Company now plans to further progress the development of this monoclonal antibody targeting the coronavirus. The Company plans a Phase 2 randomized, placebo-controlled trial in Brazil for moderate to severe hospitalized COVID-19 patients to test the drug in a more compromised group of patients.
Context for the Research
Recent studies suggest that the pathogenesis of pulmonary inflammation in Covid-19 includes an abnormal host response or overreaction of the immune system in patients. Therefore, nasal treatment with Foralumab, a fully human anti-CD3 mAb, to modulate the immune system and to stimulate Tregs, is a scientifically logical approach for the treatment of Covid-19. Foralumab is also the only monoclonal antibody that can be dosed nasally or orally due to its ability to effect systemic immunity via the epithelial lining of the nose, respiratory tract and gut.
The company shared in a recent press release that the study is expected to serve as a further proof of concept for Foralumab’s novel method of nasal delivery, as well as its safety and efficacy as a potent, systemic anti-inflammatory therapeutic in more severe Covid-19 patients.
What is Foralumab?
Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients with Crohn’s disease with decreases in the classic side effects of cytokine release syndrome and improves the overall safety profile of Foralumab. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that whilst targeting the T cell receptor, orally administered Foralumab modulates immune responses of the T cells, enhances regulatory T-cells (Tregs), and thus provides therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura M. et al., 2017). Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of Tregs.
Covid-19 enters through the nasal and respiratory passage; accordingly, the proprietary nasal formulation and nasal delivery of Foralumab to modulate immunity are expected to delay progression of the disease and to provide immediate relief to Covid-19 patients.
Dr Neil Graham, Chief Medical Officer at Tiziana Life Sciences, commented, “We are excited about this next important step in our goal to validate our drug candidate and our novel delivery system as a promising and innovative approach to immunomodulatory therapy for Covid-19 and other mutant variants. By focusing on moderating the inflammatory consequences of the SARS CoV2 virus, we hope to have a therapy that has efficacy irrespective of local viral variants.”
Principal Investigator Point of View
Professor Howard Weiner, the Robert L Kroc Professor of Neurology at the Harvard Medical School and Director and Founder of the Partners Multiple Sclerosis Center, reported recently, “I am pleased to see this novel dosing concept for anti-CD3 advance to a phase 2 clinical trial. These types of human trials are important to validate the successful studies we conducted in animal models of several inflammatory diseases.”
Tiziana Life Sciences Background
Tiziana Life Sciences is a dual listed (NASDAQ: TLSA & LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to Milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn’s Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (“mAb”) in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (“T1D”), inflammatory bowel disease (“IBD”), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (“IL6R”) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
Founded in 2013, the company is based in the United Kingdom. Traded at 2.75 the company doesn’t have a lot of cash on hand—about $10 million. Like many small biotech ventures, the quest for capital represents an ongoing endeavor. The company has locations in both the UK and America.
Howard Weiner, MD, the Robert L Kroc Professor of Neurology at the Harvard Medical School and Director and Foudner of the Partners Multiple Sclerosis Center, Co-Director of the Ann Romney Center for Neurologic Diseases at the Brigham & Women’s Hospital